Re: Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial

被引：0
|
作者：
Taneja, Samir S.
机构：
来源：
JOURNAL OF UROLOGY | 2020年 / 203卷 / 01期
关键词：
RADIATION;
D O I：
10.1097/01.JU.0000611500.33954.d2
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [1] Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
    Widmark, Anders
    Gunnlaugsson, Adalsteinn
    Beckman, Lars
    Thellenberg-Karlsson, Camilla
    Hoyer, Morten
    Lagerlund, Magnus
    Kindblom, Jon
    Ginman, Claes
    Johansson, Bengt
    Bjornlinger, Kirsten
    Seke, Mihajl
    Agrup, Mans
    Fransson, Per
    Tavelin, Bjorn
    Norman, David
    Zackrisson, Bjorn
    Anderson, Harald
    Kjellen, Elisabeth
    Franzen, Lars
    Nilsson, Per
    LANCET, 2019, 394 (10196): : 385 - 395
  • [2] Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
    Lott, Felipe
    INTERNATIONAL BRAZ J UROL, 2020, 46 (06): : 1100 - 1101
  • [3] Re: Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer (HYPO-RT-PC): Patient-Reported Quality-Of-Life Outcomes of a Randomised, Controlled, Non-Inferiority, Phase 3 Trial
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2021, 206 (04): : 1064 - 1064
  • [4] Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC) : patient-reported quality-of-life outcomes of a randomised, controlled, 3 trial
    Fransson, Per
    Nilsson, Per
    Gunnlaugsson, Adalsteinn
    Beckman, Lars
    Tavelin, Bjorn
    Norman, David
    Thellenberg-Karlsson, Camilla
    Hoyer, Morten
    Lagerlund, Magnus
    Kindblom, Jon
    Ginman, Claes
    Johansson, Bengt
    Bjornlinger, Kirsten
    Seke, Mihajl
    Agrup, Mans
    Zackrisson, Bjorn
    Kjellen, Elisabeth
    Franzen, Lars
    Widmark, Anders
    LANCET ONCOLOGY, 2021, 22 (02): : 235 - 245
  • [5] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial
    Aluwini, Shafak
    Pos, Floris
    Schimmel, Erik
    Krol, Stijn
    van der Toorn, Peter Paul
    de Jager, Hanja
    Alemayehu, Wendimagegn Ghidey
    Heemsbergen, Wilma
    Heijmen, Ben
    Incrocci, Luca
    LANCET ONCOLOGY, 2016, 17 (04): : 464 - 474
  • [6] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial
    Aluwini, Shafak
    Pos, Floris
    Schimmel, Erik
    van Lin, Emile
    Krol, Stijn
    van der Toorn, Peter Paul
    de Jager, Hanja
    Dirkx, Maarten
    Alemayehu, Wendimagegn Ghidey
    Heijmen, Ben
    Incrocci, Luca
    LANCET ONCOLOGY, 2015, 16 (03): : 274 - 283
  • [7] HYPOFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY FOR PROSTATE CANCER: 5-YEAR ONCOLOGIC OUTCOMES OF THE DUTCH RANDOMIZED PHASE 3 HYPRO TRIAL
    Wortel, Ruud
    Incrocci, Luca
    Aluwini, Shafak
    Schimmel, Erik
    Krol, Stijn
    van der Toorn, Peter-Paul
    de Jager, Hanja
    Dirkx, Maarten
    Ghidey, Wendim
    Heijmen, Ben
    Pos, Floris
    JOURNAL OF UROLOGY, 2016, 195 (04): : E142 - E143
  • [8] Re: Hypofractionated Radiotherapy versus Conventionally Fractionated Radiotherapy for Patients with Intermediate-Risk Localised Prostate Cancer: 2-Year Patient-Reported Outcomes of the Randomised, Non-Inferiority, Phase 3 CHHiP Trial
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2016, 196 (05): : 1445 - 1445
  • [9] Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
    Wilkins, Anna
    Mossop, Helen
    Syndikus, Isabel
    Khoo, Vincent
    Bloomfield, David
    Parker, Chris
    Logue, John
    Scrase, Christopher
    Patterson, Helen
    Birtle, Alison
    Staffurth, John
    Malik, Zafar
    Panades, Miguel
    Eswar, Chinnamani
    Graham, John
    Russell, Martin
    Kirkbride, Peter
    O'Sullivan, Joe M.
    Gao, Annie
    Cruickshank, Clare
    Griffin, Clare
    Dearnaley, David
    Hall, Emma
    LANCET ONCOLOGY, 2015, 16 (16): : 1605 - 1616
  • [10] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
    Dearnaley, David
    Syndikus, Isabel
    Mossop, Helen
    Khoo, Vincent
    Birtle, Alison
    Bloomfield, David
    Graham, John
    Kirkbride, Peter
    Logue, John
    Malik, Zafar
    Money-Kyrle, Julian
    O'Sullivan, Joe M.
    Panades, Miguel
    Parker, Chris
    Patterson, Helen
    Scrase, Christopher
    Staffurth, John
    Stockdale, Andrew
    Tremlett, Jean
    Bidmead, Margaret
    Mayles, Helen
    Naismith, Olivia
    South, Chris
    Gao, Annie
    Cruickshank, Clare
    Hassan, Shama
    Pugh, Julia
    Griffin, Clare
    Hall, Emma
    LANCET ONCOLOGY, 2016, 17 (08): : 1047 - 1060
12345